Partial Epigenetic Reprogramming (Yamanaka Factor Therapy)
Current understanding
Partial epigenetic reprogramming — transient expression of Yamanaka factors (typically OSK) via AAV to roll back epigenetic age without dedifferentiating cells — remains a mechanism-plausible longevity hypothesis with animal-model support (animal-model) and no completed human outcome trials. Life Biosciences has a formal optic-neuropathy program in the clinic pipeline; separately, KHL Foundation reports longevity-community individuals received AAV reprogramming constructs through medical-tourism providers ahead of any sanctioned first-in-human readout (anecdotal-biohack). No peer-reviewed human safety or efficacy data exist as of this entry.
Evidence log
- 2026-10-07 — KHL Foundation Reports the Likely First Human Partial Epigenetic Reprogramming Treatments: cross-connection with longevity-clinics: Medical-tourism clinics are reportedly the delivery channel for the first unsanctioned human AAV reprogramming treatments, placing an unproven gene therapy inside the longevity-clinic sector. (novelty: 4)